SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC.

Sichuan Goldstone Asia Pharmaceutical Inc.

300434

CNE100001YX5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
8.52 ^CNY	-2.29%		-4.80%	-22.97%

26/04	Sichuan Goldstone Asia Pharmaceutical Inc. Proposes Final Cash Dividend for 2023	CI
25/04	Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Sichuan Goldstone Orient New Material Equipment Co., Ltd. Approves Final Cash Dividend for the Year 2020

May 25, 2021 at 01:13 am IST

Sichuan Goldstone Orient New Material Equipment Co. Ltd. at its Annual General Meeting of 2020 on 21 May 2021, approved profit distribution plan of CNY 0.000000000 per 10 shares (tax included) for 2020.

Latest news about Sichuan Goldstone Asia Pharmaceutical Inc.

Sichuan Goldstone Asia Pharmaceutical Inc. Proposes Final Cash Dividend for 2023	27/04	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Hangzhou Solipharma Technology Development Co., Ltd. announced that it expects to receive CNY 69.4857 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc., Hangzhou Huolongguo Investment Management Co., Ltd. and another investor	28/12	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Approves Management Appointments	26/12	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) added to S&P Global BMI Index	18/23/18	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/22/24	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	25/22/25	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/21/26	CI
Gao Yaping completed the acquisition of 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong.	16/21/16	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	26/21/26	CI
Gao Yaping signed an equity transfer agreement to acquire 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong for approximately CNY 170 million.	30/21/30	CI
Sichuan Goldstone Orient New Material Equipment Co., Ltd. Approves Final Cash Dividend for the Year 2020	25/21/25	CI
Sichuan Goldstone Asia Pharmaceutical Inc. signed Equity Acquisition agreement to acquire 65.40% stake in Zhejiang Jiande Zhengfa Pharmaceutical Co.Ltd from group of shareholders for approximately CNY 150 million	20/21/20	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	26/21/26	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21/21/21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Announces Management Changes	20/20/20	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	28/20/28	CI
Hangzhou Innovative Chinese Medicine Standardization Research Institute Co., Ltd. announced that it expects to receive CNY 6 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc.	28/20/28	CI
Gao Yaping completed the acquisition of 5% stake in Sichuan Goldstone Asia Pharmaceutical Inc. from Xie Shihuang, Chen Shaojiang and Zhi Ruoyu.	22/20/22	CI
Sichuan Goldstone Asia Pharmaceutical Inc. cancelled the acquisition of Jiangxi JuRenTang Pharmaceutical Company Limited from Hu Liuhe, Liu Min, Hu Xiaoping, and Hu Xuping.	19/20/19	CI

Chart Sichuan Goldstone Asia Pharmaceutical Inc.

Duration

Period

Chart Sichuan Goldstone Asia Pharmaceutical Inc.

More charts

Company Profile

Sichuan Goldstone Asia Pharmaceutical Inc., formerly Sichuan Goldstone Orient New Material Equipment Inc, is a China-based company principally engaged in the production and sales of pharmaceutical products, as well as drug agency business. Its main products include health products, cracks and small cracks. The Company is also engaged in the machinery manufacturing business, as well as property leasing and management business. Its machinery products mainly include steel reinforced plastic pipe production line, bead winding steel reinforced pipe production line, production line equipment parts and other equipment. The Company mainly operates its businesses in domestic market.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC.	-22.97%	484M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.49%	42.32B
OTSUKA HOLDINGS CO., LTD.	+15.56%	21.29B
SANDOZ GROUP AG	+19.33%	15.29B
CIPLA LIMITED	+18.65%	14.36B
ZYDUS LIFESCIENCES LIMITED	+50.98%	12.81B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.06%	6.58B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.51B

Generic Pharmaceuticals

Sichuan Goldstone Asia Pharmaceutical Inc.

Equities

300434

CNE100001YX5

Pharmaceuticals

Sichuan Goldstone Orient New Material Equipment Co., Ltd. Approves Final Cash Dividend for the Year 2020

Latest news about Sichuan Goldstone Asia Pharmaceutical Inc.

Chart Sichuan Goldstone Asia Pharmaceutical Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals